SKIN The Journal of Cutaneous Medicine

Neil J. Korman, Thierry Passeron, Yukari Okubo, Jerry Bagel, Richard B. Warren, Lynda Spelman, Kevin Winthrop, Kim Hoyt, Thomas Scharnitz, Subhashis Banerjee, Diamant Thaçi, Mona Shahriari, Linda Stein Gold

Page s419

PDF

Deucravacitinib, an Oral Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-blinded, Placebo-controlled Trial (PSORIATYK SCALP)

Kristina Callis Duffin, Christopher E. M. Griffiths, Matthias Hoffmann, Andrew Blauvelt, Eugene Balagula, Andrew Napoli, Ying-Ming Jou, Rachel Dyme, Virginia Hala, Andreas Pinter, Mark Lebwohl

Page s420

PDF

Real-World Achievement of Skin Clearance Targets and Improved Quality of Life With Risankizumab in Psoriasis Patients With Moderate Skin Involvement (BSA ≥ 3–10%)

Bruce Strober, Manish Patel, Mark I Kaldas, Greg St John, Vishvas Garg, Adam P Sima, Thomas Eckmann, Alicia Beeghly, April Armstrong

Page s421

PDF

Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program

Mark Lebwohl, Richard B. Warren, Shinichi Imafuku, Jerry Bagel, April W. Armstrong, Thierry Passeron, Subhashis Banerjee, Matthew J. Colombo, Thomas Scharnitz, Kim Hoyt, Diamant Thaçi, Andrew Blauvelt

Page s422

PDF

Deucravacitinib in Plaque Psoriasis: 4-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials

April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Akimichi Morita, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A. Papp, Matthew J. Colombo, John Vaile, Eleni Vritzali, Kim Hoyt, Carolin Daamen, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt

Page s423

PDF

Real-world Patient Use and Perception, Satisfaction, and Adherence with a Calcipotriol and Betamethasone Dipropionate PAD-cream for the Treatment of Plaque Psoriasis

José Luis López Estebaranz, Hjalmar Kurzen, Marta Menendez, Giulia Greta Dradi, Jordi Galvan

Page s424

PDF

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients With Moderate to Severe Scalp Psoriasis: Improvement in Scalp-Related Quality of Life and Symptoms in the Phase 3b/4 Multicenter, Randomized, Double-Blinded, Placebo-Controlled PSORIATYK SCALP Trial

Steven R. Feldman, Jerry Bagel, Matthias Hoffmann, Andrew Napoli, Chun-Yen Cheng, Rachel Dyme, Eugene Balagula, Yichen Zhong, Steven E. Kempers, Christopher E. M. Griffiths

Page s425

PDF

Treatments Used Among Patients with Psoriasis: A First Look at a New Patient-Centered Psoriasis Registry

Alexis Ogdie, Joel Gelfand, Laetitia N’Dri, Ying Wu, Thomas Scharnitz, Kaleb Michaud

Page 10.25251/skin.8.supp.426

PDF

Provider Burden Associated With Apremilast Adverse Events

Lana Schmidt, Ying Wu, Vardhaman Patel, Danielle Gentile, Djibril Liassou, Jason Sharpe, Courtney Omary, Monica Ahlquist, Bruce Feinberg

Page s427

PDF

Deucravacitinib in Moderate to Severe Plaque Psoriasis: Comorbidities and Use of Prior and Concomitant Medication in Patients Enrolled in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Joseph F. Merola, Alice B. Gottlieb, Nehal N. Mehta, Matthew J. Colombo, Monica Elias, Francesco De Leonardis, Ying-Ming Jou, Neil J. Korman

Page s428

PDF

Efficacy of Deucravacitinib in Plaque Psoriasis Across a Range of Body Surface Area Involvement: Post hoc Analysis of the Randomized, Double-Blinded, Placebo-Controlled, Phase 3b/4 PSORIATYK SCALP Trial

Andrew Blauvelt, Diamant Thaçi, David M. Pariser, Andrew Napoli, Eugene Balagula, Chun-Yen Cheng, Rachel Dyme, Linda Stein Gold, Mark Lebwohl

Page s429

PDF

Efficacy of Deucravacitinib in Moderate to Severe Scalp Psoriasis: Analysis of Complete Clearance of Scalp Disease and Symptoms

Linda Stein Gold, Andrew Blauvelt, Leon Kircik, Andrew Napoli, Chun-Yen Cheng, Rachel Dyme, Eugene Balagula, Jerry Bagel, Mark Lebwohl

Page s430

PDF

Bimekizumab Efficacy and Safety Over 48 Weeks in US and Canadian Patients with Psoriasis who had a Treatment Interruption After 3 Years of Treatment: Results from BE RADIANT

Mark Lebwohl, Kim Papp, Benjamin Ehst, Mark Lomaga, Phoebe Rich, Bruce Strober, April Armstrong, José M. López Pinto, Markus Kaspar, Delphine Deherder, Maggie Wang, Ronald Vender

Page s431

PDF

Bimekizumab 4-year Efficacy in High-impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from BE BRIGHT

Joseph F. Merola, Alice B. Gottlieb, Jennifer Soung, Philip Hampton, Andreas Pinter, Melinda Gooderham, Akimichi Morita, Sarah Kavanagh, Nancy Cross, Susanne Wiegratz, Carle Paul

Page s432

PDF

Bimekizumab Long-term Efficacy in Patients with Moderate to Severe Plaque Psoriasis After Switching From Adalimumab, Ustekinumab, or Secukinumab: Results from Up to 4 Years of Total Treatment from BE BRIGHT and BE RADIANT

Georgios Kokolakis, George Han, David Pariser, Antonio Costanzo, Richard G. Langley, Rhys Warham, Balint Szilagyi, Bertram Knapp, Mark Lebwohl

Page s433

PDF

Bimekizumab Clinical Efficacy in Important Body Regions and Health-related Quality of Life in Patients with Plaque Psoriasis: Data from Four Phase 3/3b Comparator-controlled Trial Periods

April Armstrong, Boni Elewski, Phoebe Rich, Matthias Augustin, José-Manuel Carrascosa, Ronald Vender, Jérémy Lambert, José M. López Pinto, Bengt Hoepken, Sarah Kavanagh, Luis Puig

Page s434

PDF

Bimekizumab Efficacy and Safety in Patients With Psoriatic Arthritis Who Had Skin and Nail Psoriasis at Baseline: Up to 2-year Results From Two Phase 3 Studies

Diamant Thaçi, Akihiko Asahina, Wolf Henning Boehncke, Alice B. Gottlieb, Mark Lebwohl, Richard B. Warren, Barbara Ink, Rajan Bajracharya, Jason Coarse, Joseph F. Merola

Page s435

PDF

Bimekizumab Safe and Effective Self-administration Using 2 mL Devices by Patients with Moderate to Severe Plaque Psoriasis: Results from Two Multicenter, Randomized, Open-label Studies

Jerry Bagel, Daljit Tatla, Bertram Knapp, Thomas Vaux, Bengt Hoepken, Michael Sebastian

Page s436

PDF

Bimekizumab 4-year Maintenance of Responses in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from the BE BRIGHT Open-label Extension Phase 3 Trial

Andrew Blauvelt, Peter Foley, Richard G. Langley, Curdin Conrad, David Rosmarin, Ricardo Romiti, Maggie Wang, Balint Szilagyi, Bengt Hoepken, Richard B. Warren

Page s437

PDF

Brodalumab Versus Ustekinumab in Obese Patients With Moderate-to-Severe Plaque Psoriasis

Sylvia Hsu, April Armstrong, Lawrence Green, Mark Lebwohl, Abby Jacobson

Page s438

PDF

Fixed-Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion and Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis on Areas With Body Hair: Maintenance of Treatment Effect

George Han, Edward Lain, Linda Stein Gold, Abby Jacobson

Page s439

PDF

Demonstration of the Clinical Utility of a Psoriasis Precision Medicine Tool: Findings from the MATCH Study Show Altered Physician Behavior Leads to Improved Patient Outcomes

Tobin Dickerson, Bruce Strober, Michael Bukhalo, April Armstrong, David Pariser, Leon Kircik, Paul Montgomery, III

Page s440

PDF

Zasocitinib (TAK-279), a Selective, Oral TYK2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis

Vivian Laquer, Leon H. Kircik, Neil Sadick, Jamie Weisman, Jessamyn Blau, Wenwen Zhang, Jonathan Uy, Warren Winkelman, Melinda Gooderham

Page s441

PDF

Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis

Melinda Gooderham, Christopher Bunick, Leon H. Kircik, Charles Lynde, Lone Skov, Jessamyn Blau, Wenwen Zhang, Jonathan Uy, Warren Winkelman, Diamant Thaçi

Page s442

PDF

Real-World Switch Rates of Risankizumab and Other Biologics in Psoriasis Patients With Psoriatic Arthritis

April W. Armstrong, Manish Patel, Zachary R. Babcock, Chao Li, Jashin J. Wu

Page s443

PDF

Psoriatic Arthritis

Maintenance of Response to Risankizumab in Patients With Psoriatic Arthritis: A 4-Year Analysis of the KEEPsAKE 1 and 2 Trials

Andrew Östör, Lila Glotfelty, Jonathon Rocco, Cuiyong Yue, Joseph F Merola

Page s444

PDF

Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 1 Trial

Frank Behrens, Mauro Keiserman, Kim Papp, Douglas White, Angela Crowley, Tshepiso Madihlaba, Thomas Iyile, Kyle Carter, Ahmed Soliman, Doug Ashley, Lily Glotfelty

Page s445

PDF

Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 2 Trial

Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Ana Biljan, Jonathon Rocco, Fang Liu, Ahmed Soliman, Doug Ashley, Lila Glotfelty, Alan Kivitz

Page s446

PDF

Retrospective Analysis of the Impact of Screening for Psoriatic Arthritis (PsA) with the Psoriasis Epidemiology Screening Tool (PEST) in Clinical Dermatology Practice

Lawrence Rasouliyan, Uche Ndefo, Amanda Mummert, Amanda Althoff, Robert Low

Page s447

PDF

Atopic Dermatitis

Utilization and Duration of Systemic Corticosteroid Exposure in Atopic Dermatitis Patients After the Introduction of Advanced Therapies: A Population-Based Study From the United States

Christopher Bunick, Ruth Ann Vleugels, Mark Lebwohl, Ayman Grada, Emma Xiaomeng Yue, Lani Wegrzyn, Elvira D'Andrea

Page s448

PDF

Long-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies

Naiem T Issa, Raj Chovatiya, Jordan Talia, Tiago Torres, Kilian Eyerich, Brian M Calimlim, Yang Yang, Alena Pechonkina, Alvaro Moreira, Ayman Grada, Christopher G Bunick

Page s449

PDF

Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry

Jonathan I. Silverberg, Melinda Gooderham, Christopher G. Bunick, Brian Calimlim, Ayman Grada, Yolanda Muñoz Maldonado, Alvin Li, Nicole Fergestrom, Eric Simpson

Page s450

PDF

Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b/4 LEVEL UP Study

Christopher Bunick, Nina Magnolo, Angela Moore, Gao Xinghua, Charles Lynde, Nadia Ibrahim, Ayman Grada, Gweneth Levy, Brian Calimlim, Xiaoqiang Wu, Yolanda Armendariz, Kilian Eyerich

Page s451

PDF

Optimized Second-Generation IL-4Rα Inhibition: Structural and Molecular Dynamics Properties of Rademikibart Fab-IL-4Rα Complex

Yuanjun Shi, Minh Ho, Haote Li, Raul Collazo, Christopher Bunick

Page s452

PDF

Efficacy and Safety of Ruxolitinib Cream by Anatomic Region in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3

Dareen Siri, Amy Paller, April Armstrong, Linda Stein Gold, Howard Kallender, Daniel Sturm, Haobo Ren, Lawrence Eichenfield

Page s453

PDF

Drying of Opzelura® (Ruxolitinib) Cream 1.5%: Implications for Clinical and Real-World Use

Haydar Abdalghafor, Janel Torsiello, Daniel Sturm, Adnan Nasir, Russell Elliott, Ahmad Naim

Page s454

PDF

Association of Ruxolitinib Cream Initiation With Continued Reduction in Use of Other Topical Treatments, Oral Corticosteroids, and Biologics for Atopic Dermatitis

Jinan Liu, Karishma Desai, Chia-Chen Teng, Grace Stockbower, Peter Chen, Vincent Willey, Daniel Sturm

Page s455

PDF

Half-life-extended Monoclonal Antibody APG777 for Atopic Dermatitis: Design of the Phase 2 APEX Study

Emma Guttman-Yassky, Andrew Blauvelt, Melinda Gooderham, Kenji Kabashima, Marilia Oliveira, Li Xie, Angela Wilson, Carl Dambkowski, Kristine Nograles, Jonathan Silverberg

Page s456

PDF

Dupilumab Demonstrates a Higher Likelihood of Achieving Improvements in Signs, Symptoms, and Quality of Life vs. Tralokinumab at Week 16: Results from a Bucher Indirect Treatment Comparison

Yann Cabon, Boya Chandrasekhar, Chien-chia Chuang, Zhixiao Wang, Ana Rossi, Kerry Noonan, Mike Bastian

Page s457

PDF

Patient and Parent/Caregiver Satisfaction with Efficacy and Cosmetic Elegance of Tapinarof Cream 1% Once Daily in a Long-term Extension Trial in Adults and Children Down to Age 2 Years with Atopic Dermatitis

Adelaide A. Hebert, James Del Rosso, Sandra Marchese Johnson, Lawrence J. Green, Sarah Serrao, Philip M. Brown, David S. Rubenstein, Anna Tallman

Page s458

PDF

Achievement of No-to-minimal Itch and Sleep Improvement with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Eric Simpson, Dareen D. Siri, Raj Chovatiya, Mona Shahriari, Autumn F. Burnette, Brittany G. Craiglow, Philip M. Brown, Anna Tallman

Page s459

PDF

Skin Clearance, Treatment Response Off-therapy, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Robert Bissonnette, Linda Stein Gold, Leon Kircik, Eric Simpson, Lawrence F. Eichenfield, John Browning, Adelaide A. Hebert, Andrew F. Alexis, Weily Soong, Stephen C. Piscitelli, Anna Tallman, David S. Rubenstein, Philip M. Brown, Jonathan I. Silverberg

Page s460

PDF

Why Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from TARGET-DERM AD Registry

Jonathan I. Silverberg, Christopher G. Bunick, Brian M. Calimlim, Ayman Grada, Keith D. Knapp, Breda Munoz, Julie M. Crawford, Chibuzo Obi, Amy S. Paller

Page s461

PDF

Persistent Inadequate Disease Control and Therapeutic Inertia in Moderate-to-Severe Atopic Dermatitis: A 12-month Longitudinal Analysis of Real-world Outcomes from the TARGET-DERM AD registry

Lawrence F. Eichenfield, Ayman Grada, Keith Knapp, Breda Munoz, Julie M. Crawford, Jonthan I. Silverberg

Page s462

PDF

Impact of Therapeutic Inertia on Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis: A 12-Month Longitudinal Study from the TARGET-DERM AD Registry

Brenda Simpson, Ayman Grada, Keith Knapp, Breda Munoz, Julie M. Crawford, Jonathan I. Silverberg

Page s463

PDF

Alopecia

Differentiating between Central Centrifugal Cicatricial Alopecia, Traction Alopecia, and Alopecia Areata in Black Patients: Photographic Examples from a Clinical Trial

Amy McMicheal, Susan Taylor, Valerie Callender, Tiffany Mayo, Susan Ball, Fionn McSwiney, Najwa Somani, Chesanna Kindred

Page s464

PDF

Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata

Ziad Reguiai, Leila Asfour, Delphine Staumont-Sallé, Ángela Hermosa-Gelbard, Andrea Sechi, Dalia Wajsbrot, Rahmat Adejumo, Deborah Woodworth, Alexandre Lejeune

Page s465

PDF

Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials

Ruth Ann Vleugals, Arash Mostaghimi, Rodney Sinclair, Bianca Maria Piraccini, Angelina Sontag, Najwa Somani, Karen Denning, Ayush Srivastava, Brett King

Page s466

PDF

Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US

Samantha K. Kurosky, Liza Takiya, Kent Hanson, Griffith Bell, Yi-Chien Lee, Genevieve Gauthier

Page s467

PDF

Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials

Arash Mostaghimi, Cheshana Kindred, Pedro Herranz Pinto, Masato Mizuashi, Dalia Wajsbrot, Rahmat Adejumo, Helen Tran, Liza Takiya

Page s468

PDF

Race and Ethnicity Sub-Groups of Alopecia Areata Patients have Differing Clinical Characteristics: TARGET-DERM AA

Maria K Hordinsky, Claire C Bristow, Sven G. Richter, Ahmed M. Soliman, Keith Knapp, Breda Munoz, Julie M. Crawford, Amy S. Paller, Shane Chapman, Lara Wine Lee, Natasha A. Mesinkovska, Benjamin N. Unger

Page s469

PDF

Demographics and Disease Characteristics of Patients with Alopecia Areata with Comorbid Atopic Dermatitis, Vitiligo or Anxiety/Depression: TARGET-DERM AA

Natasha A Mesinkovska, Sven G. Richter, Claire C Bristow, Ahmed M Soliman, Julie M Crawford, Keith D Knapp, Breda Munoz, Lara Wine Lee, M. Shane Chapman, Amy S Paller, Benjamin N Ungar, Maria K Hordinsky

Page s470

PDF

Generic vs. Disease-Specific Patient Reported Outcome (PRO) Instruments for Assessing HRQoL Burden Among Patients Diagnosed with Alopecia Areata: Evidence from TARGET-DERM AA

Benjamin N Ungar, Ahmed M. Soliman, Claire C. Bristow, Sven G. Richter, Breda Munoz, Julie M. Crawford, Keith D. Knapp, Natasha A. Mesinkovska

Page s471

PDF

A Novel Nutraceutical Gummy for Hair Regrowth in Women: A Case Series

Annyella Douglas, Leena Ramani, Spencer Hawkins, Matt Leavitt

Page s472

PDF

Hidradenitis Suppurativa

Bimekizumab Efficacy and Safety Through 2 years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II trials and Open-Label Extension BE HEARD EXT

Christos C Zouboulis, Amit Garg, Christopher J. Sayed, Gregor Jemec, Georgios Kokolakis, John R. Ingram, Akimichi Morita, Pratiksha Dokhe, Ingrid Pansar, Robert Rolleri, Christina Crater, Asim Datye, Alexa B. Kimball

Page s473

PDF

Bimekizumab Effect on the Need for Concomitant Rescue Interventions by HiSCR Response Level in Patients with Moderate to Severe Hidradenitis Suppurativa from BE HEARD I&II

Falk G. Bechara, Seth Forman, Amit Garg, Philippe Guillem, Hesel H. van der Zee, Evangelos J. Giamarellos-Bourboulis, Akimichi Morita, Bartosz Lukowski, Robert Rolleri, Pratiksha Dokhe, Nicola Tilt, Iltefat Hamzavi

Page s474

PDF

Bimekizumab impact on draining tunnels: A dynamic assessment in patients with moderate to severe HS using pooled Week 48 results from BE HEARD I&II

Thrasyvoulos Tzellos, Jennifer Hsiao, Martina Porter, Farida Benhadou, Falk G. Bechara, Melinda Gooderham, Hidetoshi Takahashi, Christos C Zouboulis, Ingrid Pansar, Robert Rolleri, Nicola Tilt, Christopher Sayed

Page s475

PDF

Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II

Jacek C Szepietowski, Hadar Lev-Tov, Vivian Y. Shi, Sylke Schneider-Burrus, Antonio Costanzo, Koremasa Hayama, Jérémy Lambert, Tom Vaux, Bartosz Lukowski, Robert Rolleri, Alice B Gottlieb

Page s476

PDF

Bimekizumab cumulative clinical benefit in patients with moderate to severe hidradenitis suppurativa through 1 year of the BE HEARD I&II phase 3 trials

Amit Garg, April Armstrong, Howard Sofen, Antonio Martorell-Calatayud, Maurizio Podda, Toshifumi Nomura, Susanne Wiegratz, Jérémy Lambert, Robert Rolleri, Nicola Tilt, Christos C Zouboulis

Page s477

PDF

Barriers and facilitators to quality HS biologic care and outcomes for the Medicaid population across US states

Steven Daveluy, Brindley Brooks, Brent Hazelett, Iltefat Hamzavi, Ginette A. Okoye, Laura Bush, Jasmine I. Espy, Danuta Marchi, Matthew Rudberg, Tae Oh, Stephanie Goldberg

Page s478

PDF

Microwave Energy for Managing Hidradenitis Suppurativa

Nicole Bielecki DMSc, MSPAS, PA-C, Aaron Hoover, MD

Page s479

PDF

Skin Cancer

Results of a Phase 2 Multicenter Study Evaluating the Safety and Tolerability of VP-315, an Investigational Therapy for Basal Cell Carcinoma

Neal Bhatia MD, Jonathan Kantor MD, Lawrence Green MD, Jonathan Weiss MD, Cynthia Willson RN, BSN, Susan Cutler DMD, Jayson Rieger PhD, MBA, David K. Glover ME, PhD, Pamela Rumney RN, CCRC, Thomas F. Haws, Gary Goldenberg MD

Page s480

PDF

Results of a Phase 2 Multicenter Study to Evaluate the Efficacy of VP-315, an Investigational Therapy for Basal Cell Carcinoma

Jonathan Kantor MD, Neal Bhatia MD, Lawrence Green MD, Jonathan Weiss MD, Kenneth Y. Tsai, MD, PhD, Cynthia Willson RN, BSN, Susan Cutler DMD, Jayson Rieger PhD, MBA, David K. Glover ME, PhD, Pamela Rumney RN, CCRC, Thomas F. Haws, Gary Goldenberg MD

Page s481

PDF

Microwave Energy for Treatment of Superficial and in situ Squamous Cell Carcinoma

Mark S. Nestor, MD, PhD, Angelica Marrero-Perez, MD, Aysham Chaudry, DO, Robert Vanaria

Page s482

PDF

Evaluating the safety and efficacy of aminolevulinic acid 20% topical solution activated by blue light in the treatment of facial cutaneous squamous cell carcinoma in situ

Aysham Chaudry, DO, Angelica Marrero-Perez, MD, Robert J. Vanaria, Vishnu Bhupalam, Mark S. Nestor, MD, PhD

Page s483

PDF

Expert Consensus-Based Recommendations on the Use of Photodynamic Therapy in Actinic Keratosis Patients

Dr. Vishal A. Patel, Dr. Sarah T. Arron, Dr. Brian Berman, Dr. M. Shane Chapman, Dr. Anokhi Jambusaria-Pahlajani, Dr. George Martin, Dr. Anthony M. Rossi, Dr. Todd Schlesinger, Dr. Nathalie C. Zeitouni, Dr. Neal Bhatia

Page s484

PDF

Safety and Efficacy of Photodynamic Therapy with ALA 10% Topical Gel Activated by Red Light versus ALA 20% Topical Solution Activated by Blue Light for the Treatment of Actinic Keratosis on the Upper Extremities: A Blinded Randomized Study

Dr. Payvand Kamrani, Dr. Maya Firsowicz, Dr. Misha Zarbafian, Dr. Kavita Darji, Dr. Raheel Zubair, Dr. Lisa Ishii, Dr. Mitchel Goldman, Dr. Monica Boen

Page s485

PDF

Pilot study utilizing short contact protocols for treatment of actinic keratoses (AK) with ALA gel-red light photodynamic therapy (PDT)

Jessica Johnson, Jackson Hanna, Dr. Amy S. Nowacki, Sanjay Anand, Alan Shen, Dr. Edward Maytin

Page s486

PDF

Generalized Pustular Psoriasis

Real-world safety of spesolimab in generalized pustular psoriasis: Evidence from an expanded access program in Argentina

María Laura Galimberti, María Lapadula, Rosana Veira, Nichiren Pillai, Rafael Sani Simões, Ana Rodriguez Castelli, Natalia Dominguez, Glenda Vilchez, Lucas Sheridan, Amy Weatherill, Xuemei Ding

Page s487

PDF

Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial

Joseph Merola, Bruce Strober, Alice Gottlieb, Arash Mostaghimi, Jason Hawkes, Jason Guercio, Ming Tang, Christian Thoma, Mark Lebwohl

Page s488

PDF

Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial

Arash Mostaghimi, Bruce Strober, Joseph Merola, Alice Gottlieb, Boni Elewski, Jason Guercio, Ming Tang, Christian Thoma, Mark Lebwohl

Page s489

PDF

Spesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial

Alice Gottlieb, Bruce Strober, Joseph Merola, Arash Mostaghimi, Aaron Farberg, Jason Guercio, Ming Tang, Christian Thoma, Mark Lebwohl

Page s490

PDF

Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time: Results from the EFFISAYIL® 2 trial

Bruce Strober, Joseph Merola, Alice Gottlieb, Arash Mostaghimi, Jennifer Hsiao, Jason Guercio, Ming Tang, Christian Thoma, Mark Lebwohl

Page s491

PDF

Four-weekly dosing intervals with subcutaneous spesolimab appear to be required for optimal prevention of generalized pustular psoriasis flares: Data from the EFFISAYIL® 2 and EFFISAYIL® ON trials

Diamant Thaci, Akimichi Morita, Bruce Strober, Tiago Torres, Andreas Pinter, Angelo Marzano, James Krueger, Ming Tang, Patrick Hofmann, Christian Thoma, Mark Lebwohl

Page s492

PDF

Acne & Rosacea

Dermal and Systemic Pharmacokinetics of Oral DFD-29 (minocycline hydrochloride modified release capsules, 40 mg) vs Oral Doxycycline 40 mg in Healthy Subjects

Dr. Adelaide Hebert, Dr. Srinivas Sidgiddi

Page s493

PDF

Efficacy and Safety of Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Participants with Moderate-to-Severe Acne: The Patient Journey

Hilary Baldwin, Julie C. Harper, Joshua A Zeichner, Zoe D Draelos, Lawrence F Eichenfield, Michael Gold, Linda Stein Gold, Leon H Kircik, Eric Guenin

Page s494

PDF

Efficacy and Safety of Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Black Participants with Moderate-to-Severe Acne

Valerie D Callender, Andrew F Alexis, Neal Bhatia, Julie C Harper, Eric Guenin, Hilary Baldwin

Page s495

PDF

Antibacterial Activity of Clindamycin/BPO in Combination With Adapalene

Ahmed Gamal, Mohamed Eltoukhi, Ali Elabbasi , James Q Del Rosso, Mahmoud Ghannoum

Page s496

PDF

Efficacy and Safety of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel: Post Hoc Analysis by Baseline Disease Severity

Michael Gold, Edward (Ted) Lain, Julie C Harper, Hilary Baldwin, Linda Stein Gold, Eric Guenin

Page s497

PDF

Miscellaneous

Environmental Impact and Sustainability Associated with the Practice of Dermatology

Robert J. Vanaria, Vishnu Bhupalam, Angelica Marrero-Perez, MD, Aysham Chaudry, DO, Nardin Awad, DO, Mark S. Nestor, MD, PhD

Page s498

PDF

Pharmacodynamic effects and exploratory efficacy of afimetoran, a TLR7/8 inhibitor, in patients with cutaneous lupus erythematosus

Jasmine Saini, Stanislav Ignatenko, Kristina Chadwick, Lin Zhu, Huynh Yen Thanh Bach, Hazem Karabeber, Michelle Dawes, Melanie Harrison, Leon Carayannopoulos, Gopal Krishna, Fareeda Hosein, Frédéric Baribaud

Page s499

PDF